Oxurion NV
XBRU:OXUR

Watchlist Manager
Oxurion NV Logo
Oxurion NV
XBRU:OXUR
Watchlist
Price: 0.2965 EUR Market Closed
Market Cap: 396.2k EUR
Have any thoughts about
Oxurion NV?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

High Profitability Stocks
Biotechnology Industry

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Oxurion NV

Revenue
263k EUR
Cost of Revenue
-159k EUR
Gross Profit
104k EUR
Operating Expenses
-12.1m EUR
Operating Income
-12m EUR
Other Expenses
-7m EUR
Net Income
-19m EUR

Margins Comparison
Oxurion NV Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
BE
Oxurion NV
XBRU:OXUR
396.2k EUR
40%
-4 556%
-7 213%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
301B USD
67%
28%
9%
US
Amgen Inc
NASDAQ:AMGN
162B USD
60%
19%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.5B USD
86%
40%
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
115.4B USD
78%
38%
0%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
138B AUD
52%
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.6B USD
87%
30%
34%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
NL
argenx SE
XBRU:ARGX
34.1B EUR
89%
-22%
-14%
Country BE
Market Cap 396.2k EUR
Gross Margin
40%
Operating Margin
-4 556%
Net Margin
-7 213%
Country FR
Market Cap 6T USD
Gross Margin
0%
Operating Margin
-17 527%
Net Margin
-21 040%
Country US
Market Cap 301B USD
Gross Margin
67%
Operating Margin
28%
Net Margin
9%
Country US
Market Cap 162B USD
Gross Margin
60%
Operating Margin
19%
Net Margin
13%
Country US
Market Cap 127.5B USD
Gross Margin
86%
Operating Margin
40%
Net Margin
-5%
Country US
Market Cap 115.4B USD
Gross Margin
78%
Operating Margin
38%
Net Margin
0%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Operating Margin
-370%
Net Margin
-392%
Country AU
Market Cap 138B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 88.6B USD
Gross Margin
87%
Operating Margin
30%
Net Margin
34%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country NL
Market Cap 34.1B EUR
Gross Margin
89%
Operating Margin
-22%
Net Margin
-14%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Oxurion NV Competitors

Country Company Market Cap ROE ROA ROCE ROIC
BE
Oxurion NV
XBRU:OXUR
396.2k EUR
214%
-205%
179%
-727%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
301B USD
56%
4%
15%
11%
US
Amgen Inc
NASDAQ:AMGN
162B USD
56%
5%
9%
10%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.5B USD
-3%
-2%
24%
-74%
US
Gilead Sciences Inc
NASDAQ:GILD
115.4B USD
1%
0%
23%
13%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
138B AUD
16%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.6B USD
17%
13%
13%
16%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
34.1B EUR
-8%
-7%
-12%
-31%
Country BE
Market Cap 396.2k EUR
ROE
214%
ROA
-205%
ROCE
179%
ROIC
-727%
Country FR
Market Cap 6T USD
ROE
115%
ROA
-391%
ROCE
275%
ROIC
3 093%
Country US
Market Cap 301B USD
ROE
56%
ROA
4%
ROCE
15%
ROIC
11%
Country US
Market Cap 162B USD
ROE
56%
ROA
5%
ROCE
9%
ROIC
10%
Country US
Market Cap 127.5B USD
ROE
-3%
ROA
-2%
ROCE
24%
ROIC
-74%
Country US
Market Cap 115.4B USD
ROE
1%
ROA
0%
ROCE
23%
ROIC
13%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country AU
Market Cap 138B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 88.6B USD
ROE
17%
ROA
13%
ROCE
13%
ROIC
16%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country NL
Market Cap 34.1B EUR
ROE
-8%
ROA
-7%
ROCE
-12%
ROIC
-31%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top